Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...

Recent FDA approvals include new therapies for AD, HS, and plaque psoriasis, impacting patients with skin of color. Tapinarof cream, roflumilast foam, and delgocitinib are notable topical treatments ...

The global dermatology market is driven by increasing skin disorder prevalence, aging demographics, and technological innovations like teledermatology and nanotechnology. The influence of social media ...

Eczema, also known as atopic dermatitis, is a chronic, noncontagious skin disorder that causes itchy, scaly patches of skin.

Daewoong Pharmaceutical’s subsidiary ‘Daewoong Pet’ is jointly developing the world’s first treatment for sarcopenia in ...

Earlier this year, Maetzold was named one of just 10 finalists selected from a pool of 586 applicants to the Executive of the ...

Discover an interview with Astrid Haaskjold Lossius on harmonised paediatric atopic dermatitis treatment for improved care ...

The approval was based on the TRuE-AD3 trial, which evaluated the safety and efficacy of ruxolitinib in pediatric patients aged 2 to 11 years with atopic dermatitis.

The U.S. Food and Drug Administration has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with ...

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseasesPhase 1b ...

AI’s responses about atopic dermatitis improved from 2024 to 2025, but information about skin of color remains limited.

Patients with moderate-to-severe atopic dermatitis achieve similar improvements in skin severity, itch, and quality of life with JAK inhibitors, regardless of prior dupilumab response, a study shows.